Análisis de sobrevida global y libre de enfermedad en pacientes con mieloma múltiple que recibieron trasplante autólogo de progenitores hematopoyéticos en la Unidad de Trasplante del hospital de SOLCA en la ciudad de Guayaquil, desde el año 2010 al 2020.

Abstract

The present study aimed to analyze the overall survival and progression-free survival rates in patients with multiple myeloma who received autologous hematopoietic progenitor cell transplants in the Transplant Unit of SOLCA Hospital in Guayaquil, from 2010 to 2020. Methodologically, the study was designed as a retrospective, descriptive, cross-sectional, and observational study, with a sample size of 74 patients. The findings suggest that the prevalence of the disease in the study sample was 32.03%; the average age of onset was ≤ 55 years (59.5%), with a prevalence in the male population (64.9%). Before transplantation, 56.8% of patients presented with the initial stage of the disease; 62.16% of patients did not experience relapses; At 5 years after transplantation, 68.9% of patients were alive (censored), while 31.1% had died. When the analysis was extended to 7.5 years, the survival rate was 59.5% and the mortality rate was 40.5%. At 10 years, 58.1% remained alive, while 41.9% had died.